tumors including breast or ovarian cancer in the same individual; (3) 46 families with two cases of breast cancer in first-or second-degree relatives; in addition to (4) 11 breast cancer cases diagnosed with breast cancer at or below the age of 40 (median 38, range 25-40 years). The unselected breast cancer cohort consisted of 1083 consecutive breast cancer cases diagnosed at the Oulu University Hospital during the years 2000-2016 (with a mean age at diagnosis 58 years) and were unselected for the family history of cancer and age at disease onset. This study included informed consent from all participating individuals, and it was approved by the Ethical Board of the Northern Ostrobothnia Health Care District.
Only one index case from the hereditary cohort was identified as a carrier (1/225, 0.44%, P = 1.0, odds ratio [OR] = 0.79, 95% confidence interval [CI] 0.1-6.4, Supplemental Table 1 ). She was diagnosed with breast cancer at the age of 43 years. There were five additional breast cancer cases in the family, but only one of them (breast cancer 54 years, melanoma 40 years) was identified to carry MLH3 p. Ser1188Ter (Supplemental Table 2 , Fam#1). As three healthy female family members were also identified as MLH3 p. Ser1188Ter carriers, there was no evidence for MLH3 p. Ser1188Ter segregation with the disease within this family. In the unselected cohort, six MLH3 p.Ser1188Ter carriers were identified (6/1083, 0.55%, P = 1.0, OR = 0.98, 95% CI 0.3-2.9, Supplemental Table 1 ) with mean age at disease onset 63 years (minimum 50 years, maximum 85 years). Of these, three had a family history of other than breast cancer (Supplemental Table 2 , Unsel#1-6). The frequency of MLH3 p. Ser1188Ter in the studied breast cancer cohorts (7/1308, 0.54%, P = 1.0, OR = 0.95, 95% CI 0.3-2.7, Supplemental  Table 1 ) did not differ from the population frequency (7/1239, 0.56%) in this geographical region, arguing against association with breast cancer risk. No MLH3 p.Ser1188Ter homozygotes were observed. Altogether these results indicate that based on the performed case-control comparison MLH3 p.Ser1188Ter is unlikely to be a significant contributor to breast cancer risk, at least when heterozygous.
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